替换
查找内容:
替换为:
全部替换
插入链接
链接网址:
链接显示标题:
请选择网址类型
点我插入链接
插入文件
文件名称:
文件显示标题:
请选择文件类型
点我插入文件
发现错误 发表观点

原文内容

反馈意见

提交 正在提交..... 反馈历史

复制下面的地址分享给好友

确定 正在提交.....
train

你好,

关闭
提交 重做 重新开始 关闭
跳转
  • 新建同级
  • 新建子级
  • 删除
  • 重命名
选择收藏夹
新建收藏夹
公开

取消 确定

1. 基本信息
姓名:
企业:
职位:
联系方式:
邮箱:
2. 请在此填写您的问题,我们将优先安排答疑
提交

报名成功!
课程观看链接如下:
请添加课程助理微信,获得更多信息:
确认
确定
取消 确认

识林

  • 知识
  • 视频
  • 社区
  • 政策法规
    • 国内药监
    • FDA
    • EU
    • PIC/S
    • WHO
    • ICH
    • MHRA
    • PMDA
    • TGA
  • 研发注册
    • 概览
    • 监管动态
    • 研究专题
  • 生产质量
    • 概览
    • 监管动态
    • 各国GMP
    • 中国GMP
    • 中国GMP指南
    • GMP对比
    • 检查缺陷
    • 研究专题
  • 主题词库
  • 帮助中心
  • 关于识林
    • 识林介绍
    • 识林FAQs
    • 功能介绍
    • 团队诊断
    • 联系我们
  • 30天免登录

    忘记密码?

FDA 将用于分子诊断设备的寨卡病毒参考序列集用于支持紧急使用授权和510(k)提交的产品检测

首页 > 资讯 > FDA 将用于分子诊断设备的寨卡病毒参考序列集用于支持紧急使用授权和510(k)提交的产品检测

页面比对

出自识林

FDA 将用于分子诊断设备的寨卡病毒参考序列集用于支持紧急使用授权和510(k)提交的产品检测
寨卡病毒
页面比对
笔记

2019-11-25 FDA

跳转到: 导航, 搜索

FDA Zika virus reference panel for molecular-based diagnostic devices supports product testing for Emergency Use Authorization and 510(k) submissions

In response to the urgent need for performance assessment of diagnostic devices that detect Zika virus (ZIKV), scientists at the U.S. Food and Drug Administration (FDA) developed reference panel composed of vials containing different concentrations of the virus’s genetic material that manufacturers can use to evaluate the performance of their ZIKV virus nucleic acid test (NAT). NAT tests detect the genetic material of microorganisms in samples such as blood, urine, or other fluids.

FDA’s Center for Devices and Radiological Health and the Center for Biologics Evaluation and Research collaborated on developing and producing the panel, which is now available to qualified companies on request.

ZIKV, which carries its genetic material in the form of RNA, triggered a public health crisis when it appeared in 2015, spreading from Brazil to other areas, such as Puerto Rico and the US Virgin Islands. While most people infected with the virus have no symptoms, fever, rash, joint pain, and red eyes can occur. In more serious cases, the disease can cause the neurologic disorder Guillain-Barré Syndrome or, if transmitted from mother to fetus, microcephaly, a disorder that can be fatal. Therefore, the availability of in vitro testing devices that provide early and specific diagnosis of ZIKV infection is critical to public health responses to the disease.

NAT is the most sensitive and specific diagnostic method during the early stage of ZIKV infection. Therefore, the development of the reference panel for Zika RNA (Zika FDA-RP) is important because the data generated using this panel enables FDA to directly compare the performance of different NATs under the same conditions. This is especially critical when FDA is comparing differently designed NAT tests while considering an emergency use authorization (EUA) for such a diagnostic device.

The panel comprises five vials of heat-inactivated ZIKV strains, two in concentrated stocks (S1 and S2) and three diluted concentrations prepared from those two strains (S3, S4, S5).

FDA researchers grew ZIKV in animal cells and prepared a series of five concentrations of material from these cell culture supernatant stocks, which they designated S1-S5. Manufacturers use the Zika reference panel to test the performance of their devices. FDA discloses to companies requesting the vials the concentrations of ZIKV in S1 and S2, so the manufacturers can determine the limit of detection of their devices (lowest quantity of a ZIKV genome distinguishable from a blank value); but the concentrations in S3-S5 are not disclosed, enabling “blind” testing of NAT assays by each company to corroborate both the reported limit of detection as well as the proficiency in handling the reference panel. In this way, FDA is able to directly compare the sensitivity of different diagnostic assays using the same reference vials.

FDA has issued EUAs to 15 NAT-based assays for ZIKV, 13 of which are still on the market.

TITLE

A Zika Reference Panel for Molecular-Based Diagnostic Devices as a US Food and Drug Administration Response Tool to a Public Health Emergency

J Mol Diagn 2019, 21: 1025e1033; url

AUTHORS

Mayra García,* Rafaelle Fares-GusmaoϮ Kim Sapsford,* Caren Chancey,Ϯ Andriyan Grinev,Ϯ Stephen Lovell,* Uwe Scherf,* and Maria RiosϮ

*Office of in Vitro Diagnostics and Radiological Devices, Center for Devices and Radiological Health and

ϮOffice of Blood Research and Review, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland

【来源】
FDA Zika virus reference panel for molecular-based diagnostic devices supports product testing for Emergency Use Authorization and 510(k) submissions

【相关内容】

  • Donor Screening Recommendations to Reduce the Risk of Transmission of Zika Virus by Human Cells, Tissues, and Cellular and Tissue-Based Products
  • Revised Recommendations for Reducing the Risk of Zika Virus Transmission by Blood and Blood Components
取自“https://login.shilinx.com/wiki/index.php?title=FDA_%E5%B0%86%E7%94%A8%E4%BA%8E%E5%88%86%E5%AD%90%E8%AF%8A%E6%96%AD%E8%AE%BE%E5%A4%87%E7%9A%84%E5%AF%A8%E5%8D%A1%E7%97%85%E6%AF%92%E5%8F%82%E8%80%83%E5%BA%8F%E5%88%97%E9%9B%86%E7%94%A8%E4%BA%8E%E6%94%AF%E6%8C%81%E7%B4%A7%E6%80%A5%E4%BD%BF%E7%94%A8%E6%8E%88%E6%9D%83%E5%92%8C510(k)%E6%8F%90%E4%BA%A4%E7%9A%84%E4%BA%A7%E5%93%81%E6%A3%80%E6%B5%8B”
上一页: FDA批准Voxelotor治疗镰状细胞病
下一页: FDA_努力帮助提高生物类似和可互换胰岛素产品的开发效率
相关内容
相关新闻
  • 加拿大卫生部更新生物制品和血...
  • FDA 修订法规取消对生物制品...
  • 取消过时的FDA检查安排规定因...
  • FDA 颁布最终法规取消过时的...
  • 德国默克测试机器学习实时平台...
热点新闻
  • ICH 发布新 Q1 稳定性指南...
  • 【直播】25年4月全球法规月报...
  • 【识林新文章】中国无菌附录对...
  • 【识林新工具】AI知识助手,AI...
  • VHP(过氧化氢蒸汽)的“脆弱...

 反馈意见

Copyright ©2011-2025 shilinx.com All Rights Reserved.
识林网站版权所有 京ICP备12018650号-2 (京)网药械信息备字(2022)第00078号
请登录APP查看
打开APP